This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 24 August 2022
Number of pages:33
This Market Spotlight report covers the Chemotherapy-Induced Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence of CIA is difficult to determine due to inconsistencies in definition and variations in the severity of anemia, region, cancer type, and stage.
Approved drugs in the cancer-related anemia space target erythropoietin receptor, transforming growth factor-beta and superfamily, angiogenesis, E3 ubiquitin ligase, and the immune system. The majority of marketed drugs are administered via the intravenous or subcutaneous routes, with one product being available in an oral formulation.
The only industry-sponsored drug in active clinical development for cancer-related anemia is in Phase III. The only industry-sponsored drug in active clinical development for cancer-related anemia targets hypoxia-inducible factorprolyl hydroxylase. It is administered via the oral route.
The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 23.7%, and the average probability a drug advances from Phase III is 83.3%. Drugs, on average, take 10.8 years from Phase I to approval, compared to 9.9 years in the overall hematology space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson
21 RECENT EVENTS AND ANALYST OPINION
21 Roxadustat for CIA (April 6, 2021)
24 PROBABILITY OF SUCCESS
25 REVENUE OPPORTUNITY
27 CLINICAL TRIAL LANDSCAPE
28 Sponsors by status
29 Sponsors by phase
30 Recent events
LIST OF FIGURES
17 Figure 1: Overview of pipeline drugs for CIA in the US
17 Figure 2: Pipeline drugs for CIA, by company
17 Figure 3: Pipeline drugs for CIA, by drug type
18 Figure 4: Pipeline drugs for CIA, by classification
24 Figure 5: Probability of success in the marrow or peripheral blood stimulator pipeline
27 Figure 6: Clinical trials in CIA
27 Figure 7: Top 10 drugs for clinical trials in CIA
28 Figure 8: Top 10 companies for clinical trials in CIA
29 Figure 9: CIA trials status
30 Figure 10: CIA trials sponsors, by phase
LIST OF TABLES
11 Table 1: Chemotherapy-treated patients with CIA, by grade, in the US
14 Table 2: Marketed drugs for CIA
19 Table 3: Pipeline drugs for CIA in the US
21 Table 4: Roxadustat for CIA (April 6, 2021)
25 Table 5: Historical global sales, by drug ($m), 2017–21
26 Table 6: Forecasted global sales, by drug ($m), 2022–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.